QUIGLEY CORPORATION (QGLY)

[mjm2005]

http://biz.yahoo.com/e/051114/qgly8-k.html

Form 8-K for QUIGLEY CORP

14-Nov-2005

Results of Operations, Other Events, Financial Statements and Exhibits


ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

On November 14, 2005, The Quigley Corporation (the "Company") issued a press release announcing its financial results for the third quarter ended September 30, 2005. The full text of the press release is attached hereto as Exhibit 99.1. The press release corrects the calculation of the weighted average of earnings per share due to a change in the calculation of the number of shares outstanding. Net income for the third quarter ended September 30, 2005 was $3.0 million, or $0.23 per share compared to $177,000, or $0.01 per share, for the same period last year. Net income for the nine months ended September 30, 2005 was $1.1 million, or $0.08 per share, compared to a net loss of $1.5 million, or ($0.13) per share, for the same period last year.

The information furnished pursuant to Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 hereto, shall not be considered "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of such section, nor shall it be incorporated by reference into future filings by the Company under the Securities Act of 1933, as amended or under the Securities Exchange Act of 1934, as amended, unless the Company expressly sets forth in such future filing that such information is to be considered "filed" or incorporated by reference therein.



ITEM 8.01 OTHER EVENTS.

On November 14, 2005, the Company issued a press release providing updates on the status of its pharmaceutical pipeline. The full text of the press release is attached hereto as Exhibit 99.1.



ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(c) Exhibits.

Exhibit No. Description
----------- -----------

99.1 Press Release dated November 14, 2005 reporting third
quarter ended September 30, 2005 preliminary unaudited
earnings and updates on the status of the Company's
pharmaceutical pipeline.